Kim Blish, PhD
2009 Graduate of Molecular Medicine PhD program
Ph.D., Molecular Medicine, 2009
Wake Forest University
School of Medicine
BS (Chemistry), 2002
Eastern Nazarene College, Quincy, MA.
In collaboration with Human Genome Sciences (Rockville, MD), a new gene product was identified that is down-regulated in certain types of tumors, most notably kidney and breast tumors. This new product is believed to be a member of the bone morphogenetic protein (BMP) growth factor family. We propose to name this gene product BARC, BMP Antagonist Regulated in Cancer. Our hypothesis is that BARC functions extracellularly to inhibit pro-growth or differentiation signals from the BMP pathway. Loss of the BARC product would conceivably contribute to carcinogenesis.
My work involves: 1) Genotyping of the BARC allele from patient samples; 2) Starting the protein expression characterization and functional studies of BARC in renal and breast cell cultures and 3) Comparing BARC expression in patient samples versus normal controls, in the hopes of examining a potential marker or therapeutic target for kidney cancer.
Honors and Awards:
2005 BC043274, “A Novel Bone Morphogenetic Protein Antagonist as a Breast Cancer Growth Suppressor.” Breast Cancer Research Program, CDMRP, Department of Defense. Pre-doctoral Traineeship Award
2005 1st Place Student Presentation, WFU Cancer Biology Department
2002 Honors Distinction, summa cum laude, Eastern Nazarene College
2002 Senior Award in Biochemistry- American Institute of Chemists
2001 James Norris-Richard Flack Summer Undergraduate Research Scholarship. Northeastern Section of the American Chemical Society.
1998 National Merit Scholarship Award
Professional Society Memberships:
2004-06 American Physician Scientist Association (APSA)
Wake Forest University Institutional Representative.
2007 American Association for Cancer Research (AACR)
Blish, KR, Willingham MC, Du W, Birse CE, Krishnan SR, Brown JC, Wang W, Hawkins GA, Garvin AJ, D'Agostino RB, Torti SV, Torti FM. A Novel, Human Bone Morphogenetic Protein Antagonist is Down regulated in Renal Cancer. Mol Biol Cell. 2008 Feb;19(2):457-64.
April 2007: Annual Meeting of the American Association for Cancer Research (AACR), Los Angeles, CA. Kimberly R. Blish, Mark C. Willingham, Wei Du, Charles E. Birse, Surekha R. Krishnan, Julie C. Brown, Wei Wang, Gregory A. Hawkins, A. Julian Garvin, Ralph B. D'Agostino Jr., Frank M. Torti, Suzy V. Torti. The human bone morphogenetic protein antagonist BARC is downregulated in renal cancers In: American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract #3785.
April 2006: BARC: A Novel, Human BMP Antagonist Downregulated in Breast and Renal Cancers. K.R. Blish, M.C. Willingham, W. Du, C. Birse, J.C. Brown, M.A. Triplette, A.J. Garvin, F.M. Torti, S.V. Torti. Poster for ASCI/AAP Joint Meeting. The Fairmont Hotel, Chicago, Illinois, April 29, 2006.
January 2004:SCGF in Breast Cancer Growth and Detection. K.R. Blish, J. Brown, M. Willingham, C. Birse, F.M. Torti, and S.V. Torti. Poster for the Breast Cancer Center of Excellence Retreat. Comprehensive Cancer Center of Wake Forest University. January 15, 2004. Winston-Salem, NC.
Blish, K.R.; Ibdah, J.A. Maternal heterozygosity for a mitochondrial trifunctional protein mutation as a cause for liver disease in pregnancy. Med. Hypotheses. 2005. 64(1): 96-100.
Rose, K.; Zhao, Y.; Ibdah, JA. Liver Disease in Pregnancy Associated with Maternal Heterozygosity for A Mitochondrial Trifunctional Protein Mutation and A Normal Fetal Genotype. For presentation at Digestive Disease Week, the joint conference of the AASLD, AGA, ASGE, and SSAT. May 17-22, 2003. Orange County Convention Center, Orlando, Florida.
Rose, K.; Hall, LH. E-State Modeling of Fish Toxicity Independent of 3D Structure Information. SAR QSAR Environ. Res. 2003. 14 (2): 113-129
Rose, K.; Hall, LH; Kier, LB. Modeling blood-brain barrier partitioning using the electrotopological state. J. Chem. Inf. Comput. Sci. 2002. May – June; 42(3): 651-66.
Rose, K. Hall, L.H. Modeling of Blood-Brain Barrier Permeability for Drug and Drug-Like Compounds. The Nucleus. (Northeastern Section of the American Chemical Society Journal). 2002 Feb; 80(6): 11-15.
For a listing of additional publications, refer to PubMed, a service provided by the National Library of Medicine